Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tusamitamab ravtansine + pembrolizumab in CEACAM5+ non-squamous NSCLC
NCT04524689Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Oct 2020
- Primary completion
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of tusamitamab ravtansine in non-small cell lung cancer (NSCLC), sponsored by Sanofi. Started Oct 2020; status: terminated.
02
Drugs
tusamitamab ravtansine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04524689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04524689.